Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Dopamine Agonists Global Market Report 2025
Download Free Sample Buy Now
Global Dopamine Agonists Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Dopamine Agonists Global Market Report 2025

By Product Type (Ergot Based Dopamine Agonists, Non Ergot Based Dopamine Agonists), By Route of Administration (Oral, Parenteral, Transdermal Patches), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Pharmacies), By Application (Parkinson's Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia), By End User (Hospitals, Clinics, Home Care Settings) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Dopamine Agonists Market Overview

• Dopamine Agonists market size has reached to $2.57 billion in 2024

• Expected to grow to $3.61 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%

• Growth Driver: The Rising Prevalence Of Neurological Disorders Fueling Growth In The Market Due To Increasing Cases Of Alzheimer's And Parkinson's Diseases

• Market Trend: Improved Adherence And Outcomes With Flexible-Dose Dopamine Therapy

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Dopamine Agonists Market?

Dopamine agonists are medications that activate dopamine receptors in the brain, mimicking the effects of natural dopamine. They are used to manage disorders caused by low dopamine activity or impaired dopamine signaling.

The main product types of dopamine agonists are ergot-based dopamine agonists and non-ergot-based dopamine agonists. Ergot-based dopamine agonists are medications derived from ergot alkaloids that activate dopamine receptors in the brain to help manage neurological and hormonal conditions. They have various routes of administration, such as oral, Parenteral, and transdermal patches. These medications are distributed through various channels, including hospital pharmacies, retail pharmacies, and other pharmacies. They are used for different applications, such as Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia. The key end users include hospitals, clinics, and home care settings.

Dopamine Agonists Market Size and growth rate 2025 to 2029: Graph

What Is The Dopamine Agonists Market Size 2025 And Growth Rate?

The dopamine agonists market size has grown strongly in recent years. It will grow from $2.57 billion in 2024 to $2.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the increasing incidence of Parkinson’s disease, rising diagnosis of restless legs syndrome (RLS), expansion of reimbursement coverage, growing CNS disorder research funding, and increasing healthcare awareness.

What Is The Dopamine Agonists Market Growth Forecast?

The dopamine agonists market size is expected to see strong growth in the next few years. It will grow to $3.61 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to the rising prevalence of neurological disorders, aging global population, increase in research and clinical trials, expansion of combination therapies, rising awareness, and diagnosis rates. Major trends in the forecast period include personalized medicine and genetic profiling, wearable drug delivery systems, AI and machine learning in drug development, extended-release formulations, and nanotechnology for drug delivery.

The forecast of 7.2% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of dopamine agonist medications sourced from Israel and Germany, thereby prolonging Parkinson's disease treatment timelines and elevating neurology care expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Dopamine Agonists Market Segmented?

1) By Product Type: Ergot Based Dopamine Agonists, Non Ergot Based Dopamine Agonists

2) By Route of Administration: Oral, Parenteral, Transdermal Patches

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies

4) By Application: Parkinson's Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia

5) By End User: Hospitals, Clinics, Home Care Settings

Subsegment:

1) Ergot-Based Dopamine Agonists: Bromocriptine, Cabergoline, Pergolide

2) Non-Ergot-Based Dopamine Agonists: Pramipexole, Ropinirole, Rotigotine, Apomorphine

What Is Driving The Dopamine Agonists Market? The Rising Prevalence Of Neurological Disorders Fueling Growth In The Market Due To Increasing Cases Of Alzheimer's And Parkinson's Diseases

Rising prevalence of neurological disorders is expected to propel the growth of the dopamine agonist market. Neurological disorders are conditions that affect the brain, spine, or nerves, causing problems with movement, thinking, or behavior. The increasing prevalence of neurological disorders is partly due to longer life expectancies, as the risk of conditions like Alzheimer's and Parkinson's rises with age. Dopamine agonists help treat neurological disorders like Parkinson's disease by stimulating dopamine receptors in the brain, improving control, and reducing symptoms. For instance, in 2024, according to the Alzheimer's Disease Facts and Figures report by the Alzheimer's Association, a US-based nonprofit voluntary health organization that focuses on Alzheimer's disease care, support, and research. In 2022, 6.5 million Americans aged 65 and older were diagnosed with Alzheimer's dementia, increasing to 6.9 million in 2024. Therefore, the rising prevalence of neurological disorders will drive the growth of the dopamine agonist industry.

Who Are The Major Players In The Global Dopamine Agonists Market?

Major companies operating in the dopamine agonists market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Intas Pharmaceuticals Ltd., UCB Pharma S.A., Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Lupin Limited, Luye Pharma Group Ltd., ACADIA Pharmaceuticals Inc., Kissei Pharmaceutical Co., Ltd., Shodhana Laboratories Pvt. Ltd., Oceanic Pharmachem Pvt. Ltd., AffaMed Therapeutics Holdings Limited, Schwarz Pharma AG

What Are The Key Trends Of The Global Dopamine Agonists Market? Improved Adherence And Outcomes With Flexible-Dose Dopamine Therapy

Major companies operating in the dopamine agonists market are focusing on innovations such as flexible-dose monotherapy to improve patient adherence, reduce side effects, and provide more personalized treatment options for neurological disorders. options for neurological disorders. Flexible-dose monotherapy is a treatment approach that uses a single drug with adjustable dosing, allowing doctors to tailor the amount to each patient's specific needs and response. For instance, in November 2024, AbbVie Inc., a US-based biopharmaceutical company, announced positive topline results from its Phase 3 TEMPO-2 trial, demonstrating that investigational tavapadon, a flexible-dose monotherapy (5-15 mg once daily), significantly improved motor function in early Parkinson's disease patients. The trial met its primary endpoint with a notable reduction in MDS-UPDRS Parts II and III scores and achieved key secondary endpoints, showing meaningful improvement in daily motor activities. Tavapadon is the first D1/D5 partial agonist being investigated for once-daily Parkinson's treatment.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Dopamine Agonists Market? AbbVie Expands Neurology Portfolio With Strategic Acquisition Of Cerevel

In August 2024, AbbVie, a US-based biopharmaceutical company, acquired Cerevel Therapeutics for $8.7 billion. With this acquisition, AbbVie aims to strengthen its neuroscience portfolio by gaining access to Cerevel Therapeutics' innovative pipeline of treatments for psychiatric and neurological disorders. Cerevel Therapeutics Holdings Inc. is a US-based biopharmaceutical company specializing in developing therapies for neurological and psychiatric disorders.

What Is The Regional Outlook For The Global Dopamine Agonists Market?

North America was the largest region in the dopamine agonists market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Dopamine Agonists Market?

The dopamine agonist market includes sales of pramipexole, ropinirole, rotigotine, apomorphine, bromocriptine, and cabergoline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Dopamine Agonists Industry?

The dopamine agonists market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the dopamine agonists industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Dopamine Agonists Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $2.73 billion
Revenue Forecast In 2034 $3.61 billion
Growth Rate CAGR of 7.2% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The dopamine agonists market covered in this report is segmented –
1) By Product Type: Ergot Based Dopamine Agonists, Non Ergot Based Dopamine Agonists
2) By Route of Administration: Oral, Parenteral, Transdermal Patches
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
4) By Application: Parkinson's Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia
5) By End User: Hospitals, Clinics, Home Care Settings Subsegment:
1) Ergot-Based Dopamine Agonists: Bromocriptine, Cabergoline, Pergolide
2) Non-Ergot-Based Dopamine Agonists: Pramipexole, Ropinirole, Rotigotine, Apomorphine
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Request for Sample
Customization ScopeExplore Purchase Options
Pricing And Purchase Options

Table Of Contents

1. Executive Summary

2. Dopamine Agonists Market Characteristics

3. Dopamine Agonists Market Trends And Strategies

4. Dopamine Agonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Dopamine Agonists Growth Analysis And Strategic Analysis Framework

5.1. Global Dopamine Agonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Dopamine Agonists Market Growth Rate Analysis

5.4. Global Dopamine Agonists Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Dopamine Agonists Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Dopamine Agonists Total Addressable Market (TAM)

6. Dopamine Agonists Market Segmentation

6.1. Global Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ergot Based Dopamine Agonists

Non Ergot Based Dopamine Agonists

6.2. Global Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

Transdermal Patches

6.3. Global Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Other Pharmacies

6.4. Global Dopamine Agonists Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Parkinson's Disease

Restless Legs Syndrome (RLS)

Hyperprolactinemia

6.5. Global Dopamine Agonists Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Clinics

Home Care Settings

6.6. Global Dopamine Agonists Market, Sub-Segmentation Of Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Bromocriptine

Cabergoline

Pergolide

6.7. Global Dopamine Agonists Market, Sub-Segmentation Of Non Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pramipexole

Ropinirole

Rotigotine

Apomorphine

7. Dopamine Agonists Market Regional And Country Analysis

7.1. Global Dopamine Agonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Dopamine Agonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dopamine Agonists Market

8.1. Asia-Pacific Dopamine Agonists Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dopamine Agonists Market

9.1. China Dopamine Agonists Market Overview

9.2. China Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dopamine Agonists Market

10.1. India Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dopamine Agonists Market

11.1. Japan Dopamine Agonists Market Overview

11.2. Japan Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dopamine Agonists Market

12.1. Australia Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dopamine Agonists Market

13.1. Indonesia Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dopamine Agonists Market

14.1. South Korea Dopamine Agonists Market Overview

14.2. South Korea Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dopamine Agonists Market

15.1. Western Europe Dopamine Agonists Market Overview

15.2. Western Europe Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dopamine Agonists Market

16.1. UK Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dopamine Agonists Market

17.1. Germany Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dopamine Agonists Market

18.1. France Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dopamine Agonists Market

19.1. Italy Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dopamine Agonists Market

20.1. Spain Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dopamine Agonists Market

21.1. Eastern Europe Dopamine Agonists Market Overview

21.2. Eastern Europe Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dopamine Agonists Market

22.1. Russia Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dopamine Agonists Market

23.1. North America Dopamine Agonists Market Overview

23.2. North America Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dopamine Agonists Market

24.1. USA Dopamine Agonists Market Overview

24.2. USA Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dopamine Agonists Market

25.1. Canada Dopamine Agonists Market Overview

25.2. Canada Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dopamine Agonists Market

26.1. South America Dopamine Agonists Market Overview

26.2. South America Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dopamine Agonists Market

27.1. Brazil Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dopamine Agonists Market

28.1. Middle East Dopamine Agonists Market Overview

28.2. Middle East Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dopamine Agonists Market

29.1. Africa Dopamine Agonists Market Overview

29.2. Africa Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dopamine Agonists Market Competitive Landscape And Company Profiles

30.1. Dopamine Agonists Market Competitive Landscape

30.2. Dopamine Agonists Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Dopamine Agonists Market Other Major And Innovative Companies

31.1. Teva Pharmaceutical Industries Ltd.

31.2. Boehringer Ingelheim International GmbH

31.3. Otsuka Pharmaceutical Co. Ltd.

31.4. Intas Pharmaceuticals Ltd.

31.5. UCB Pharma S.A.

31.6. Dr. Reddy’s Laboratories Ltd.

31.7. H. Lundbeck A/S

31.8. Lupin Limited

31.9. Luye Pharma Group Ltd.

31.10. ACADIA Pharmaceuticals Inc.

31.11. Kissei Pharmaceutical Co., Ltd.

31.12. Shodhana Laboratories Pvt. Ltd.

31.13. Oceanic Pharmachem Pvt. Ltd.

31.14. AffaMed Therapeutics Holdings Limited

31.15. Schwarz Pharma AG

32. Global Dopamine Agonists Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dopamine Agonists Market

34. Recent Developments In The Dopamine Agonists Market

35. Dopamine Agonists Market High Potential Countries, Segments and Strategies

35.1 Dopamine Agonists Market In 2029 - Countries Offering Most New Opportunities

35.2 Dopamine Agonists Market In 2029 - Segments Offering Most New Opportunities

35.3 Dopamine Agonists Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Dopamine Agonists Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Dopamine Agonists Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Dopamine Agonists Market, Sub-Segmentation Of Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Dopamine Agonists Market, Sub-Segmentation Of Non Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Dopamine Agonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Dopamine Agonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Pfizer Inc. Financial Performance
  • Table 79: Merck & Co. Inc. Financial Performance
  • Table 80: AbbVie Inc. Financial Performance
  • Table 81: Novartis AG Financial Performance
  • Table 82: GlaxoSmithKline plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Dopamine Agonists Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Dopamine Agonists Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Dopamine Agonists Market, Sub-Segmentation Of Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Dopamine Agonists Market, Sub-Segmentation Of Non Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Dopamine Agonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Dopamine Agonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Pfizer Inc. Financial Performance
  • Figure 79: Merck & Co. Inc. Financial Performance
  • Figure 80: AbbVie Inc. Financial Performance
  • Figure 81: Novartis AG Financial Performance
  • Figure 82: GlaxoSmithKline plc Financial Performance

Global Complete Nutrition Products Market Landscape: Trends and Market Share to 2029

Read More About Global Complete Nutrition Products Market Landscape: Trends and Market Share to 2029

Competitive and Market Trend Analysis of Conjugate Vaccine Industry Through 2029

Read More About Competitive and Market Trend Analysis of Conjugate Vaccine Industry Through 2029

Industry Trends Show Cosmeceuticals Market Set to Expand at 8.8% CAGR Until 2029

Read More About Industry Trends Show Cosmeceuticals Market Set to Expand at 8.8% CAGR Until 2029

Strategic Report on Cosmetic Ingredients Market: Growth Opportunities and Emerging Challenges

Read More About Strategic Report on Cosmetic Ingredients Market: Growth Opportunities and Emerging Challenges

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Central Nervous System Drugs Global Market Report 2022 – By Type (Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route O...

View Report

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Global Market Report 2025 – By Drug Type (Stimulants, Non-Stimulants), By Psychotherapy (Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychoth...

View Report

Antidepressants Global Market Report 2025 – By Product (Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhibitor (MAOI...

View Report

Antipsychotic Drugs Global Market Report 2025 – By Therapeutic Class (First Generation, Second Generation, Third Generation), By Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases), B...

View Report

Anticholinergic Drugs Global Market Report 2025 – By Type (Synthetic Compounds, Natural, Semi-Synthetic Compounds), By Route Of Administration (Parental, Oral, Topical), By Application (Overactive Bladder, Parkinson Dise...

View Report

Anti-Parkinson Drugs Global Market Report 2025 – By Drugs Class (Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergi...

View Report

Cholinergic Drugs Global Market Report 2025 – By Type (Powder, Tablet, Capsule), By Drug Type (Muscarinic Agonists, Nicotinic Agonists, Acetylcholinesterase Inhibitors), By Indication (Alzheimer's Disease, Myasthenia Gra...

View Report

Psychedelic Drugs Global Market Report 2025 – By Type (Lysergic Acid Diethylamide (LSD), Ketamine, Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Salvia), By Disease Indication (Depression, PTSD), By Origin (Natural, Sy...

View Report

Frequently Asked Questions

Dopamine agonists are medications that activate dopamine receptors in the brain, mimicking the effects of natural dopamine. They are used to manage disorders caused by low dopamine activity or impaired dopamine signaling. For further insights on this market, request a sample here

The market major growth driver - The Rising Prevalence Of Neurological Disorders Fueling Growth In The Market Due To Increasing Cases Of Alzheimer's And Parkinson's Diseases. For further insights on this market, request a sample here

The dopamine agonists market size has grown strongly in recent years. It will grow from $2.57 billion in 2024 to $2.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the increasing incidence of Parkinson’s disease, rising diagnosis of restless legs syndrome (RLS), expansion of reimbursement coverage, growing CNS disorder research funding, and increasing healthcare awareness. The dopamine agonists market size is expected to see strong growth in the next few years. It will grow to " $3.61 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to the rising prevalence of neurological disorders, aging global population, increase in research and clinical trials, expansion of combination therapies, rising awareness, and diagnosis rates. Major trends in the forecast period include personalized medicine and genetic profiling, wearable drug delivery systems, AI and machine learning in drug development, extended-release formulations, and nanotechnology for drug delivery. For further insights on this market, request a sample here

The dopamine agonists market covered in this report is segmented –
1) By Product Type: Ergot Based Dopamine Agonists, Non Ergot Based Dopamine Agonists
2) By Route of Administration: Oral, Parenteral, Transdermal Patches
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
4) By Application: Parkinson's Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia
5) By End User: Hospitals, Clinics, Home Care Settings Subsegments:
1) Ergot-Based Dopamine Agonists: Bromocriptine, Cabergoline, Pergolide
2) Non-Ergot-Based Dopamine Agonists: Pramipexole, Ropinirole, Rotigotine, Apomorphine For further insights on this market, request a sample here

North America was the largest region in the dopamine agonists market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dopamine agonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the dopamine agonists market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Intas Pharmaceuticals Ltd., UCB Pharma S.A., Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Lupin Limited, Luye Pharma Group Ltd., ACADIA Pharmaceuticals Inc., Kissei Pharmaceutical Co., Ltd., Shodhana Laboratories Pvt. Ltd., Oceanic Pharmachem Pvt. Ltd., AffaMed Therapeutics Holdings Limited, Schwarz Pharma AG . For further insights on this market, request a sample here.

Major trends in this market include Improved Adherence And Outcomes With Flexible-Dose Dopamine Therapy. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Dopamine Agonists Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon